{"name":"Bruce Cree","slug":"bruce-cree","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNd1hYMzNBdk1pT3VkUXJjYzhKeDFiaXlTbll1cmdycEVYc0xQTnNsSGl1Rmp4dkFLZTJJakwtRTdZRjFDWVpXSllvTE56VFdmRTRHZ0RObHVBNjJzUmZ0RXRXTHpzdTFaOFFsTldqdVBTMjE5UU5nck50N3l1Q25MQkFzc0VXbWFpbXBkbDNTZk1ZMFduVk5ldHRlUnVOTDNEUnpqdG5Id3VKWkphYi1rN0Z3?oc=5","date":"2024-03-03","type":"pipeline","source":"CGTLive®","summary":"Bruce Cree, MD, PhD, MAS, on the Importance of Understanding Disease Pathobiology for Novel Treatment Approaches - CGTLive®","headline":"Bruce Cree, MD, PhD, MAS, on the Importance of Understanding Disease Pathobiology for Novel Treatment Approaches - CGTLi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1mRzFWcWwtRGcyR3FrMkZwWnpsWk1HRXYwaXJTbW5NV3R1UVN4eFpuME1qRng2X2IwTVFzbjYzdlJDWEx2MWFVejZGYmFHVVVOOEYwWkxiN2dtUkptdlFmRW5CcW00WW1YaUE0?oc=5","date":"2023-10-07","type":"pipeline","source":"Wiley Online Library","summary":"Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism - Wiley Online Library","headline":"Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNUzdDcU9kNnBRT0JzYzgwdG51bUpMbTJNVHlZMHBSWHBYWVlnMG5xcGNuVFdOdExISkZKOUxpeFltYUM4VFp3X3psai1GQmVtaHBqSmxIdDRIRkdNRWNXSEh0YVV2UTV5RlJjNS01ZlN2VjFjd09qck1QTmZLeUd0cEhiQ1ZOZks2S1VzX1MyUnpCT3VSLVo1VWFWZFVoMGpSM2c?oc=5","date":"2023-01-20","type":"regulatory","source":"neurologylive.com","summary":"FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845 - neurologylive.com","headline":"FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9vWVZSN1h4WXdvRmV0THRFcWpZZXExQTFna2pURHdKU2VzSWpueXJqQTB0YVotb3BZYzRsWXZhXzVwN2dRSEVfaVlXNmV2ekxvLUhfRFZFaGJqb3NyRDlmQkVwNmFYcmV5REtydw?oc=5","date":"2021-03-16","type":"pipeline","source":"Wiley Online Library","summary":"Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker - Wiley Online Library","headline":"Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPRFhJMVE5bWJLT2JjMnlfb08tNjA0VHhZTzZLV0hiam5ockVkWFFpeEtFeU96LVZDV0tPc1pOb2Q0TTN1cTJmd1MtSE1DeWViSFV6bHBhY2ZtR2wyRXkwSmZLQjM2WHZKX29LS0R2R2hwYjl6NFdTU2dsa0JHWXFrTkwtQy03MHM3TzNwWEUzVzZIaklrREVVcndNNjVya3NybEh0TmdEODZYdFRJQ2c?oc=5","date":"2020-11-04","type":"trial","source":"neurologylive.com","summary":"Biotin in MS: Positive Takeaways From Negative Trial Results - neurologylive.com","headline":"Biotin in MS: Positive Takeaways From Negative Trial Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNV1dwZ3RQelcydG53SWd2WHZPZzBZUXhUVVQ1V1NOWkc5SDlBSlo2akdsT2RSaDUwOUJhZlZfZ2xtM21qZEhDdnRZWTNnOG53c1pNOU9YdWUyU2dSYjN6cU8xUG1jS1Fpd2xXOG9hbTJzYVBlbGJCYmluejI1WjVsNVBKM0VpY0h6Z0RUVXQtZWF1SWJFMG5FeWVNLXMwUQ?oc=5","date":"2020-10-29","type":"pipeline","source":"neurologylive.com","summary":"High-Dose Biotin Fails to Improve Disability in Progressive MS - neurologylive.com","headline":"High-Dose Biotin Fails to Improve Disability in Progressive MS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPY1dsVDhmSUlsenZVR1NvcjIxMS1RUmtXQW01UFpOUXVwRGFJdGduRm9Mbk44RjhRMUkySkxjV2JlV3JwVnF1azlNeHdsdkJndE15cENzTEpZWEE3cDZySEhycnpOQzZ4YW1oZmg0LXdTdlVwaktRZm8zX05hSERQNy1RQVF6eXhGUXRJ?oc=5","date":"2020-04-22","type":"pipeline","source":"PharmaTimes","summary":"Novartis highlights benefits of Mayzent in MS - PharmaTimes","headline":"Novartis highlights benefits of Mayzent in MS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMmFvc3JmRUUwY20zX3B4UTlsYlBNWHdxVkE3LXZ3TFFncjFfSkVVVjM0VUdoTFFkNUl2NHJwczVmMzRLamZ1N09pS3Zpb0dKY0FqcnNCb3ZvZjhHdl9yNVdhcmR6R1NMRThCeS1sMWc5QkpPby0wZlNJbzVZczd4MkV5aUxrMF9JLUMtRlFRa2NGUjZZRjVaT1RFN2VpMU1G?oc=5","date":"2018-10-11","type":"trial","source":"Fierce Pharma","summary":"Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study - Fierce Pharma","headline":"Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPNE9TRi1hQktnX2RySTVqSXIyNW4yV1pDbWpuRU5XNkxMZHByZUN3Yy1MTEEwLThGM3l2RUtqMFA5VmVIYzNqV0o3aFF1MjVvNGRtamVVbEVIQS1ESFhLVjZQRkRTNFhQR3J4RkxHVFh3X0pUU1EyMTcyNm1YVEVLYkZ3TnJzZHdldER2MU9IZGpMUXlsR2dxUS1iS1M1YXdGLWtsUGxnMWw2Y29udC0tNjJPb2tiLW1qa0hSRko3MA?oc=5","date":"2018-04-20","type":"pipeline","source":"Fierce Pharma","summary":"Novartis pads case for new MS blockbuster with disease-progression analysis - Fierce Pharma","headline":"Novartis pads case for new MS blockbuster with disease-progression analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}